多药学的操作定义及其与全因住院风险的关联:使用行政数据库的概念框架
Stefano Scotti1,2, Lorenza Scotti3, Federica Galimberti2
1Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, 20122 Milan, Italy.
Pharmacy (Basel, Switzerland)
|February 25, 2025
概括
定义多药性是复杂的,但使用累积定义每日剂量 (DDD) ≥60提供了一种一致的方法. 这种方法有助于识别患有住院等不良健康结果风险较高的患者.
科学领域:
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
- 医疗保健服务研究 医疗服务研究
背景情况:
- 多药性,即使用多种药物,与不良健康事件有关.
- 对多药学的不一致定义在研究和临床实践中造成异质性.
研究的目的:
- 建立适合行政数据库的多药学的操作定义.
- 评估不同多药学定义与全因住院风险之间的关联.
主要方法:
- 来自伯加莫当地卫生部门 (LHU) 的药房补充和住院数据的分析.
- 包括40岁以上的患者,在2017年至少有一份处方.
- 使用世卫组织标准评估多药,排除短期治疗,累计每日定义剂量 (DDD) ≥60,评估在不同的时间框架.
主要成果:
- 累计DDD≥60定义显示出患病率变异性最低 (20.47-21.16%).
- 这一定义确定了一个更复杂的老年患者队列.
- 所有探索的定义都显示了与住院风险的剂量依赖关系.
结论:
- 多药的定义显著影响了流行率估计.
- 累积DDD≥60方法为行政数据提供了更一致的衡量标准.
- 以患者为中心的策略对于评估多药店的适当性和降低风险至关重要.
更多相关视频
相关概念视频
Analysis of Population Pharmacokinetic Data
214
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
214
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
38
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
38
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
111
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
111
Hazard Ratio
76
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
76
Nonlinear Pharmacokinetics: Overview
249
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinearity can arise due to the saturation of plasma protein-binding or...
249
Pharmacovigilance
764
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
764


